Cost watchdog, citing Repatha outcomes shortfall, pitches lower price for Amgen PCSK9

14th June 2017 Uncategorised 0

PCSK9 drug makers and their pharma peers have hit out at the Institute for Clinical and Economic Review, arguing that the self-appointed cost watchdog uses flawed methods to assess new medications. Now, ICER is going even further on its claim that Amgen’s new cholesterol fighter isn’t worth what the company’s charging.

More: Cost watchdog, citing Repatha outcomes shortfall, pitches lower price for Amgen PCSK9
Source: fierce